CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.
about
Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damageTargeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and FutureIdelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potentialRole of the tumor microenvironment in mature B-cell lymphoid malignanciesThe role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemiaPharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple MechanismsBCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic LeukemiaCurrent challenges and novel treatment strategies in double hit lymphomasThe role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemiaPI3K isoform-selective inhibitors: next-generation targeted cancer therapiesNew molecular targets in mantle cell lymphomaThe B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignanciesIbrutinib (PCI-32765) in chronic lymphocytic leukemiaEmerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorderIdelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular LymphomaMolecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemiaB cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292Novel agents in mantle cell lymphomaIdelalisib for the treatment of chronic lymphocytic leukemiaLipid kinases as therapeutic targets for chronic painHow will B-cell-receptor-targeted therapies change future CLL therapy?Protein kinase inhibitors against malignant lymphomaTargeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisibSignal transduction in the chronic leukemias: implications for targeted therapiesStatus of PI3K/Akt/mTOR pathway inhibitors in lymphomaTargeting the RAS oncogene.The tumor microenvironment shapes hallmarks of mature B-cell malignancies.Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunitiesMantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsSignaling by the phosphoinositide 3-kinase family in immune cellsIdelalisib and rituximab in relapsed chronic lymphocytic leukemiaResistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1The PI3K p110δ regulates expression of CD38 on regulatory T cellsPI3Kα inhibition reduces obesity in miceHigh throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomibTargeting BTK with ibrutinib in relapsed chronic lymphocytic leukemiaHigh-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.Idelalisib may have the potential to increase radiotherapy side effects.
P2860
Q24597424-59EB3A94-D52C-405A-84C2-A02C2D1024E6Q24603171-FDFF9CD9-F638-4244-9E43-AF81177F6F42Q26746934-F0EA2EB5-9C77-4118-BE95-CFC914E5B8D6Q26747753-84C86B1B-BFEC-41ED-9589-5E4BEB910CCAQ26748775-3CADEFE0-012C-451A-ACAE-771A2A5710B7Q26751006-8DC84CB8-D0C0-4440-BDEC-0E4138A6146EQ26751444-35D57563-5DDA-4DA6-9B60-A0F24AECB56DQ26765624-9BA6F5BD-8C8A-4DCE-8016-350DBDB01FC1Q26770385-5E0F031D-BF85-4CAB-A2EF-36A278EDA79BQ26775506-EF0B188E-919A-46C8-B92A-918417FA94FDQ26781294-81558672-16DA-43B1-BD2B-EC7C754A8CF8Q26821766-D08201A4-7C5A-40AB-A569-4D13CF6B5DC1Q26822700-826CBB5C-74AF-4C6B-A937-EECBE87FAA88Q26852328-E2469E4A-8A54-4395-84E8-AA5F26CD9B5DQ26859114-FDDE0B57-BA22-46DB-BAD4-30FBE284108BQ26865645-91A4A903-E8A6-4AF6-8AC2-2789B97DB367Q27006068-10E3DB31-809A-4E31-ADA5-C4F98FAF9FC7Q27009550-72CB14E8-B8BE-40F1-B829-28588AAB662AQ27011763-4F8D4397-57CF-4A9D-8AD5-38EA83D513D9Q27015826-0901C8A8-C303-4342-889A-4510895DDB72Q27023075-3140D6F3-D3EF-4D60-B938-7BCE5FBB25E4Q27024187-3E00AB19-9D01-4B1C-8E35-DC2C752CD316Q27024212-918CFEC1-0C3C-43B4-A224-C8C579568A7AQ27025812-CAE9F20F-CEA3-4E9A-BFE4-A5E50C5B960FQ27026031-143CA1D3-199D-44F2-98F7-ED28C5E74A60Q27026544-58C2B7A6-5FFB-4356-A4EA-F392D1F04ECEQ27687198-1E562BE2-F4D1-457D-951C-8702A8CE523EQ27687567-7B8FA4EC-7F82-48C0-BECB-A5D8D47045C1Q28071384-A453018A-BBA1-468F-BC27-AE6C8F5B8031Q28075606-A1E2B2EA-8D31-4AD1-A1EA-75D098D02982Q28283677-024DE49E-4C0C-4109-B6FC-98F3F534E5C3Q28306347-A3E8E074-F0FA-4C4F-8DD4-3ABEF68BE746Q28540038-9D862E50-CC0E-4AA5-BB18-7EBDA8FB7384Q28742303-E7DFFAE7-DD38-4998-9FE5-6E4469B0F341Q28818545-4A340EAF-5DCB-4565-9214-16B882A36BECQ28818948-931C22A7-79BB-4AAA-8A5C-EE3D297A9C89Q29620690-68312455-9D82-43F3-8FD2-14F00A5D315EQ30433183-1C3D937F-E8C4-45BC-AEC8-94272FACE1A3Q31070331-7122348A-A03A-4BC8-814B-22B4B16B07F4Q32186978-324360D7-A89A-4BBD-BB1E-6F76080EE717
P2860
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
CAL-101, a p110delta selective ...... naling and cellular viability.
@en
CAL-101, a p110delta selective ...... naling and cellular viability.
@nl
type
label
CAL-101, a p110delta selective ...... naling and cellular viability.
@en
CAL-101, a p110delta selective ...... naling and cellular viability.
@nl
prefLabel
CAL-101, a p110delta selective ...... naling and cellular viability.
@en
CAL-101, a p110delta selective ...... naling and cellular viability.
@nl
P2093
P2860
P50
P1433
P1476
CAL-101, a p110delta selective ...... naling and cellular viability.
@en
P2093
Adam Kashishian
Amy J Johnson
Bart Steiner
Brian J Lannutti
Kamal D Puri
Marc M Loriaux
Mike Deininger
Neill A Giese
Roger G Ulrich
Sarah A Meadows
P2860
P304
P356
10.1182/BLOOD-2010-03-275305
P407
P577
2010-10-19T00:00:00Z